Entrada Therapeutics Target Price

See Entrada Therapeutics's analyst price targets ($13) vs the current share price.

Get informed when a big investor buys or sells

+ Follow

Share Price

$7.27

Average Target Price

$12.67

74.2% upside

3 analysts in the last 4 months

High: $17 | Low: $10

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

Date	Analyst	Price Target	Current Upside/Downside
2026-08-12	Roth Capital	$11	51.3% upside
2026-06-08	Guggenheim	$17	133.8% upside
2026-05-08	Roth Capital	$10	37.6% upside
2026-02-10	Guggenheim	$20	175.1% upside
2026-01-28	OppenheimerKostas Biliouris	$21	188.9% upside
2025-11-06	Roth Capital	$13	78.8% upside
2025-02-28	Roth Capital	$23	216.4% upside
2024-11-06	H.C. WainwrightBoobalan Pachaiyappan	$20	175.1% upside
2024-06-25	H.C. WainwrightRaghuram Selvaraju	$18	147.6% upside

Entrada Therapeutics (TRDA) FAQ

As of the most recent data, TRDA shows a target price of $13. Scroll down for historical charts and peer comparison views.

If Entrada Therapeutics moved to the average analyst target of $13, shares would be roughly 74.2% higher than $7.27. Treat that as a sentiment and modeling checkpoint rather than a precise forecast, and weigh it against your own view of Entrada Therapeutics's earnings trajectory.

Besides this target price page, Stockcircle has Entrada Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect target price (currently $13) with ownership activity and broader fundamentals.